Tag: pREset
Newly published PROST trial results find Preset non-inferior to Solitaire in...
Final results from the PROST randomised controlled trial (RCT) have been published in JAMA Neurology and—according to the study’s leading investigators—provide evidence that thrombectomy...
PROST represents “epitome” of scientific rigour, but future trials may follow...
There are multiple components of the PROST randomised controlled trial’s (RCT) design that set it apart from prior studies and make it somewhat unique...
Wallaby/Phenox announces presentation of PROST trial data at ISC 2023
Phenox, a Wallaby Medical company, has today announced the presentation of the primary results of the PROST (Preset for occlusive stroke treatment) randomised clinical...
Wallaby/Phenox announces US FDA clearance of Preset thrombectomy device
Phenox, a Wallaby Medical company, has announced the US Food and Drug Administration (FDA) 510(k) clearance of its Preset thrombectomy device for the treatment...
Phenox expands acute ischaemic stroke portfolio with global launch of pRESET...
Phenox has added to its extensive technology portfolio with the introduction of the pRESET 6-50 mechanical thrombectomy device for the treatment of acute large...
Phenox highlights benefits of longer stentriever devices with new study results
Following its acceptance into Frontiers in Neurology, Phenox has announced the results of a paper exploring the benefit of choosing a longer stentriever for...
ARTESp study of pREset device shows 62.5% positive clinical outcome after...
The treatment of mechanical thrombectomy represents a highly effective therapy in patients with acute ischaemic stroke. This was recently proven by four randomised controlled...
SITS Open stroke trial includes phenox pREset thrombectomy device
The phenox pREset and pREset LITE thrombectomy devices have been included in the study portfolio of the SITS Open clinical trial. Two other devices...
